STOCK TITAN

Rafael Holdings (RFL) Stock News, Mar-Nov 2023

RFL NYSE

Rafael Holdings, Inc. reports developments as a biotechnology company focused on pharmaceutical development and interests in clinical-stage and early-stage pharmaceutical and medical device companies. Its lead program is Trappsol® Cyclo™, a hydroxypropyl-beta-cyclodextrin product candidate evaluated for Niemann-Pick Disease Type C1, with additional cyclodextrin-related work in neurodegenerative disease.

Recurring company news covers clinical development of Cyclo Therapeutics programs, scientific presentations, patent and licensing activity, quarterly and annual financial results, and governance changes. Updates also address the company’s consolidated expenses following the Cyclo Therapeutics acquisition and its portfolio interests in healthcare and medical-device development.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.10%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.90%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
private placement
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
private placement
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
private placement
-
Rhea-AI Summary

Rafael Holdings (NYSE: RFL) announced a $5 million buyback of its Class B common stock to enhance shareholder value. CEO Bill Conkling emphasized the company's strong balance sheet and strategic opportunities in the current macroeconomic environment. The repurchase signals confidence in the company's long-term value creation strategy. The buyback will occur through open market purchases and other means, contingent upon market conditions and regulatory factors. Rafael Holdings aims to expand investments beyond biopharma, leveraging Executive Chairman Howard Jonas's expertise in identifying lucrative opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.68%
Tags
buybacks
Rhea-AI Summary

Rafael Holdings, Inc. (NYSE: RFL) reported its fiscal Q2 2023 results, highlighting a net loss of $3.3 million, or $0.13 per share, compared to a loss of $2.1 million, or $0.09 per share, in Q2 2022. As of January 31, 2023, the company had $88.9 million in cash, cash equivalents, and marketable securities. For the first half of fiscal 2023, Rafael recorded a net loss of $8.5 million, significantly reduced from $130.9 million in the prior year, which included substantial write-offs and impairments. R&D expenses decreased to $4.3 million from $5.5 million year-over-year, reflecting winding down programs at Barer Institute. General and administrative costs also declined. CEO Bill Conkling emphasized the strong balance sheet for funding pipeline assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.72%
Tags

FAQ

What is the current stock price of Rafael Holdings (RFL)?

Rafael Holdings (RFL) last closed at $0.9871.

What is the market cap of Rafael Holdings (RFL)?

The market cap of Rafael Holdings (RFL) is approximately $51.5M.